Virtu Financial LLC Buys New Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Virtu Financial LLC purchased a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 88,518 shares of the biotechnology company’s stock, valued at approximately $104,000. Virtu Financial LLC owned approximately 0.11% of CytomX Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CTMX. Jacobs Levy Equity Management Inc. lifted its holdings in shares of CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 16,359 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in CytomX Therapeutics by 10.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after purchasing an additional 26,373 shares during the last quarter. US Bancorp DE bought a new stake in CytomX Therapeutics during the third quarter worth about $40,000. Geode Capital Management LLC boosted its holdings in shares of CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of CytomX Therapeutics by 1.4% during the 2nd quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company’s stock valued at $3,324,000 after purchasing an additional 37,739 shares during the last quarter. Institutional investors own 67.77% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Monday, November 11th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $5.77.

CytomX Therapeutics Trading Up 3.8 %

CTMX opened at $1.10 on Friday. The company has a market cap of $86.08 million, a P/E ratio of 6.47 and a beta of 1.07. CytomX Therapeutics, Inc. has a 12 month low of $0.83 and a 12 month high of $5.85. The business’s 50-day moving average price is $1.06 and its 200-day moving average price is $1.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. The business had revenue of $33.43 million for the quarter, compared to analysts’ expectations of $18.92 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the firm earned $0.04 EPS. Equities research analysts forecast that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.